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Abstract
Background: Drug product data is available on the Web in a distributed fashion. The reasons lie within the
regulatory domains, which exist on a national level. As a consequence, the drug data available on the Web are
independently curated by national institutions from each country, leaving the data in varying languages, with a
varying structure, granularity level and format, on different locations on the Web. Therefore, one of the main
challenges in the realm of drug data is the consolidation and integration of large amounts of heterogeneous data into
a comprehensive dataspace, for the purpose of developing data-driven applications. In recent years, the adoption of
the Linked Data principles has enabled data publishers to provide structured data on the Web and contextually
interlink them with other public datasets, effectively de-siloing them. Defining methodological guidelines and
specialized tools for generating Linked Data in the drug domain, applicable on a global scale, is a crucial step to
achieving the necessary levels of data consolidation and alignment needed for the development of a global dataset
of drug product data. This dataset would then enable a myriad of new usage scenarios, which can, for instance,
provide insight into the global availability of different drug categories in different parts of the world.
Results: We developed a methodology and a set of tools which support the process of generating Linked Data in the
drug domain. Using them, we generated the LinkedDrugs dataset by seamlessly transforming, consolidating and
publishing high-quality, 5-star Linked Drug Data from twenty-three countries, containing over 248,000 drug products,
over 99,000,000 RDF triples and over 278,000 links to generic drugs from the LOD Cloud. Using the linked nature of
the dataset, we demonstrate its ability to support advanced usage scenarios in the drug domain.
Conclusions: The process of generating the LinkedDrugs dataset demonstrates the applicability of the
methodological guidelines and the supporting tools in transforming drug product data from various, independent
and distributed sources, into a comprehensive Linked Drug Data dataset. The presented user-centric and analytical
usage scenarios over the dataset show the advantages of having a de-siloed, consolidated and comprehensive
dataspace of drug data available via the existing infrastructure of the Web.
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Background
Accessing comprehensive drug and healthcare data on
the Web can be a challenging task. The main reason
lies in the fact that the data is available in different for-
mats, at distributed Web locations. Additionally, most
of the drug and healthcare datasets are published for
specific purposes only, so consequentially, they contain
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limited data. For instance, national drug repositories con-
tain information about drug products which are approved
and sold in the country [1–7]; websites aimed for the
general public [8–13] contain descriptive drug use infor-
mation, such as target, dosage, packaging and warnings;
websites aimed for professionals [14–16] contain more
specific drug data, such as active ingredients, chemical
formulas, drug-drug interactions, food-drug interactions,
toxicity, etc. Websites such as DrugBank [14, 17] con-
tain more comprehensive drug data. However, the drug
entries in their dataset are generic drugs, i.e. active ingre-
dients of drugs, and not actual drug products which can
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be bought by patients. Various mobile and web appli-
cations [18–22] contain information about drug prod-
ucts, but the data they use is country-specific and is
not available to the interested parties in an open for-
mat. Global drug product repositories exist as well [23–
25], but they either do not provide means of getting the
data in an open format, or are locked behind a pay-wall.
Additionally, some of them provide data for drugs reg-
istered in countries from specific world regions only, or
solely provide the name of the drug product in a specific
country.
The Linked Data approach
According to [26–29], the emergence of the Linked Data
principles has introduced new ways to integrate and con-
solidate data from various and distributed sources. The
Linked Data principles provide means and standards for
representing, storing and retrieving data over the exist-
ing infrastructure of theWeb. This enables publishing and
contextual linking of data on the Web and with it, cre-
ating a Web of data, as opposed to the current Web of
documents.
With this, the Web becomes a distributed network for
standards-based data access, usable by software agents
and machines. The interlinked nature of the distributed
datasets provides new use-cases for the end-users, which
are generally unavailable over isolated datasets. The
Linked Data approach solves the issue of having ‘data
silos’ in traditional relational database systems, silos which
cannot link to other databases without a specific code
written for the task, or specific mapping created in a data
warehousing solution.
Additionally, the schema-flexibility of RDF provides
means of independent data management and evolution,
which is very well suited for the nature of theWeb, but also
for non-Web use in environments where data de-siloing
and consolidation is needed [30, 31].
So far, as a result of the adoption of Linked Data prin-
ciples by data publishers, the Linked Open Data (LOD)
Cloud [32] has been populated with 1104 interlinked
datasets [33]. These datasets, published on the Web fol-
lowing the Linked Data principles, belong to 8 different
domains: government, publications, life sciences, user-
generated content, cross-domain, media, geographic and
social web.
Motivation
Drug and healthcare data is already available on the Web,
both as Linked Data in the LOD Cloud and as regular
data on websites and in mobile applications, intended for
human consumption. However, the drug data available
currently as Linked Data is comprised of drug entities
which are generic drugs, i.e. active ingredients of drugs,
not actual drug products registered in a specific country,
under a specific name, with a specific dosage form,
strength and price, for which an end-user might be inter-
ested. Such end-users are the patients, the pharmacists,
the doctors, but also medical institutions, pharmaceuti-
cal companies, etc, which need access to drug products
from specific countries for a multitude of user-centric and
analytical scenarios [34]: accessing general information
about drugs which can be bought in a country, accessing
information about the availability of different drugs and
drug categories in different countries, accessing pricing
information, etc.
The national drug data are generally available on the
Web, but on regular webpages and not as Linked Data.
In order to transform the data from the national drug
registries into high-quality, 5-star Linked Data [35], we
propose a set of methodological guidelines which aim to
assist drug data publishers and other interested parties
into generating a global Linked Drug Data dataset, con-
sisting of official data about drugs registered for use in
different countries. One such global Linked Drug Dataset
would be accessible by using W3C standards via the exist-
ing Web infrastructure and would enable a myriad of new
drug-analysis scenarios, including the above-mentioned
ones. It would enable further data exploitations via devel-
opment of innovative applications and services which use
the data gathered from national drug registries of different
countries in the world.
Such methodological guidelines should include steps
aimed towards modeling and aligning the data, trans-
forming the data into 5-star Linked Data, publishing the
created datasets on the Web and defining use-cases or
developing applications on top of the dataset. They should
be aimed towards assisting drug data owners and pub-
lishers, such as the national governing bodies, medical
institutions, pharmaceutical companies, pharmacies, etc.,
in publishing their data in the same aligned, Linked Data
format. Their data, once transformed into Linked Drug
Data and interlinked with the drug data already pub-
lished using the same methodology, could be used for
data-based analytics (by the medical institutions, pharma-
ceutical companies and governing bodies) or for reaching
potential customers (by pharmacies).
In this paper, we propose a set of such methodolog-
ical guidelines for consolidating drug data on a global
scale, using Linked Data. In order to support our method-
ological guidelines, we have developed a set of open and
publicly available tools, which can be reused in the pro-
cess of applying the steps from themethodology over drug
data from any country.
Using the proposed methodological guidelines and
tools, we generated the LinkedDrugs dataset which con-
sists of drug product data from twenty-three countries,
and therefore validated the methodology. For this pur-
pose we developed an automated system which gathers
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drug data from the official national drug registries of
twenty-three different countries, executes data cleaning,
aligns and transforms the data into 5-star Linked Data and
publishes them on the Web in a common, aligned and
consolidated Linked Data dataset. We then demonstrate a
set of user-centric and analytical usage scenarios over the
generated dataset, which are otherwise unavailable or very
time-consuming in a scenario where a user works with the
data available on the Web in HTML webpages.
Related work
Linked Data projects in the healthcare domain
Numerous projects and efforts have already worked on
transforming drug and healthcare data into Linked Data.
According to [33], there are currently 83 life science
datasets in the LODCloud. These datasets contain health-
care data from various subdomains, such as drugs, dis-
eases, genes, interactions, clinical trials, enzymes, etc. The
most notable are the Linking Open Drug Data (LODD)
project, Bio2RDF and the Semantic Web Health Care and
Life Sciences Interest Group at W3C.
The LODD project [36] focuses on interlinking data
about drugs already existing on the Web, as described in
[37, 38]. The data ranges from impact of the drugs on
gene expression to results of clinical trials. The aim of
the project is to enable answering of interesting scientific
and business questions by interlinking previously sepa-
rated data about drugs and healthcare. As part of their
work, they have collected datasets with over 8,000,000
RDF triples, interlinked with more than 370,000 RDF
links. However, it seems that the project has not been
updated for some time now, and Bio2RDF has taken over
the hosting and continual publication of the datasets.
Bio2RDF [39] is an open-source project which cre-
ates RDF datasets from various life science resources
and databases, and interconnects them following the
Linked Data principles into one comprehensive network
[40–42]. The latest release of Bio2RDF contains around
11 billion triples which are part of 35 datasets [43].
These datasets hold various healthcare data: clinical trials
(ClinicalTrials), drugs (DrugBank, LinkedSPL, NDC), dis-
eases (Orphanet), bioactive compounds (ChEMBL), genes
(GenAge, GenDR, GOA, HGNC, HomoloGene, MGD,
NCBI Gene, OMIM, PharmGKB, SGD, WormBase), pro-
teins (InterPro, iProClass, iRefIndex), gene-protein inter-
actions (CTD), biomedical ontologies (BioPortal), side
effects (SIDER), terminology (Resource Registry, MeSH,
NCBI taxonomy), mathematical models of biological pro-
cesses (BioModels), publications (PubMed), etc.
One of the datasets, which is a part of the LODD
cloud and Bio2RDF, is the DrugBank dataset, described in
[17]. It provides RDF data about drugs, such as chemical,
pharmacological and pharmaceutical information, taken
from an the existing DrugBank database [14, 17] of drug
information. The DrugBank RDF dataset [44] contains
over 766,000 RDF triples for 4,770 drugs. These drugs are
generic drugs, i.e. active ingredients in drug products.
The World Wide Web Consortium (W3C) has estab-
lished the SemanticWeb for Health Care and Life Sciences
Interest Group (HCLS IG) [45] to help organizations from
the health domain in their adoption of the Semantic Web
technologies. It is comprised of experts from around 30
W3C member organizations: research centers, universi-
ties, companies, health institutions, etc. Its mission is
to develop and support the use of the technologies of
the Semantic Web in the fields of healthcare, life sci-
ences, clinical research and translational medicine [46]. It
is comprised of various subgroups, which are focused on
making the biomedical data available in RDF, developing
and maintaining biomedical ontologies, etc.
In recent years, our research team gained experience in
the drug and healthcare domain by applying the Linked
Data principles and the Semantic Web technologies in the
several different scenarios.We have transformed and pub-
lished the drug product data from the Health Insurance
Fund of Macedonia as 5-star Linked Data, by connecting
it to the LODD and LOD Cloud datasets via the Drug-
Bank dataset [47]. We have since extended this dataset
with 5-star Linked Data about the Macedonian medical
institutions and drug availability lists from pharmacies
[48]. We have also used Linked Data for an analysis of
the connections between drugs and their interactions with
food, and recipes from different national cuisines, result-
ing in findings that uncovered the ingredients and cuisines
most responsible for negative food-drug interactions in
different parts of the world [49]. These projects helped us
gain insight in the domain and identify the challenges of
applying Linked Data in the domain.
Linked Datamethodologies
There are a few methodologies defined in the Linked Data
domain, which deal with the process of generating, pub-
lishing and using Linked Data. They are mainly focused
on government data, but some are domain independent.
The W3C Government Linked Data Working Group has
created official guidelines for publishing and accessing
open (government) data using the Linked Data principles
[50], and with it they suggest three existing methodologies
which can be used with the Linked (Government) Data
lifecycle. These three methodologies are: (a) the method-
ology of Hyland et al., (b) the methodology of Hausenblas
et al. and (c) the methodology of Villazón-Terrazas et al.
Hyland et al. [51] define a methodology for Linked Gov-
ernment Data, which consists of six steps. Their method-
ology is based on the specifications and best practices by
the W3C, and consists of the following steps: (1) Identify,
(2) Model, (3) Name, (4) Describe, (5) Convert, (6) Pub-
lish, and (7) Maintain. The methodology contains most
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steps which are part of the generally accepted Linked Data
lifecycle, but is missing guidelines on how to use the gen-
erated Linked Data. The authors believe that the usage of
the generated dataset should be left to the users and other
interested parties, and according to them, is not a task for
the Linked Data publisher.
Hausenblas et al. [52] state that the existing data man-
agement approaches - which assume control over the data,
the schema and the data generation - cannot be used in the
environment of the Web, due to its open and decentral-
ized nature. Their methodology consist of the following
steps: (1) Data awareness, (2) Modeling, (3) Publishing, (4)
Discovery, (5) Integration, and (6) Use-cases. It also cov-
ers most of the general Linked Data lifecycle steps, but
does not provide detailed guidelines for the process of
publishing the generated Linked Data dataset on theWeb.
Similarly to Hyland et al., based on their experience
in linked government data production, Villazón-Terrazas
et al. [53] define a set of methodological guidelines for
generating, publishing and exploiting Linked Govern-
ment Data. Their lifecycle consists of the following steps:
(1) Specify, (2) Model, (3) Generate, (4) Publish, and (5)
Exploit. This is the only existing methodology in the
Linked Data domain which covers all of the lifecycle steps,
but unfortunately is focused on government data.
In addition to these three methodologies selected by
the W3C Government Linked Data Working Group, the
LOD2 Project has developed an updated Linked Data
lifecycle for extracting, creating, enriching, linking and
maintaining Linked Data [54]. The Linked Data lifecycle
supported by the LOD2 integrated environment consists
of (1) Extraction, (2) Storage, (3) Authoring, (4) Interlink-
ing, (5) Classification, (6) Quality, (7) Evolution/Repair,
and (8) Search/Browsing/Exploration. Even though this is
the only methodology which provides software tools for
the denoted steps, and the number of steps here is larger
than in the other methodologies, it still misses some key
elements of the Linked Data lifecycle, such as the data
modeling, the definition of the URI format for the enti-
ties and the ways of publishing the generated dataset. The
provided tools are also general, and cannot be applied
in a specific domain without further work and domain
knowledge.
Results
We developed a methodology and a set of supporting
tools for the drug domain, which allowed us to streamline
the incremental process of generating high-quality Linked
Data of drug products from twenty-three countries. This
newly created dataset of drug product data, the Linked-
Drugs dataset [55], currently consists of over 248,000
drug products, interlinked with over 91,000,000 relations
denoting similarity between them, and with over 278,000
links to their corresponding active ingredients available
as Linked Data in the LOD Cloud. The LinkedDrugs
dataset enables a novel way of using drug product data, by
unlocking new user-centric and analytical usage scenar-
ios, previously unavailable over isolated and siloed drug
data repositories. These scenarios utilize the consolidated
and aligned nature of the dataset and its contextual links
to entities from the LOD Cloud. This is achieved by auto-
matically generating the additional relations in our dataset
which link the drugs between themselves, and link the
drugs with drug entities and active ingredients published
as part of other LOD Cloud datasets. Using W3C stan-
dards over the existing infrastructure of the Web, we are
then able to retrive data from these distributed datasets,
and present them to the end-users in a comprehensive
manner.
Here, we will provide a brief overview of the developed
methodological guidelines and their tools aimed at assist-
ing the data publishers during the specific steps in the
methodology, while a more in-depth description is pro-
vided in the ‘Methods’ section. We will then present the
LinkedDrugs dataset, along with the process of develop-
ing the automated system which constructs the dataset.
Then, we will present an overview of newly enabled
usage scenarios over the consolidated drug product
data.
Themethodological guidelines
Our methodological guidelines for consolidating drug
data using the Linked Data approach improve upon the
existing Linked Data methodologies and contain steps,
activities and tools which are specific to the drug data
domain. We used our experience in the domain of Linked
Healthcare Data to develop guidelines which aim to guide
data publishers through the process of generating high
quality, 5-star Linked Data in order to interlink, align and
consolidate drug data from different national drug reg-
istries or other sources of drug data. The alignment and
relationship between the existing methodologies and our
guidelines is outlined in Table 5.
Our methodology consists of five steps (Fig. 1):
(1) Domain and Data Knowledge, (2) Data Modeling and
Alignment, (3) Transformation into 5-star Linked Data,
(4) Publishing the Linked Data Dataset on the Web, and
(5) Use-cases, Applications and Services. These steps have
been developed with reuse as a primary goal; therefore,
their main focus is the encouragement of data publishers
in the drug domain to develop, modify and use reusable
components during the steps of the methodology. This
makes the Linked Drug Data lifecycle modular, i.e. con-
structed of loosely-coupled components which can be
reused in the domain. Here, by loosely-coupled we mean
components which can be used separately when neces-
sary, but which also form a seamless workflow for gener-
ating a high-quality, 5-star Linked Drug Data dataset. The
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Fig. 1 The methodology for consolidating drug data using the Linked Data approach
reuse of such components reduces development time and
increases productivity [56, 57].
Methodology supporting tools
As part of the methodological guidelines, we developed
a set of tools as reusable components which simplify the
execution of the specific steps of the methodology. Their
intent is to support the Linked Drug Data generation pro-
cess for both people from the drug domain which do not
have deeper knowledge of Linked Data, and Linked Data
publishers which do not have deeper knowledge of the
drug domain. The set consists of (a) the RDF schema,
(b) the CSV template, (c) the OpenRefine transforma-
tion script, (d) the SPARQL-based tool for extending
and interlinking the dataset and (e) the web-based tool
for automated transformation, interlinking and publish-
ing of the generated Linked Drug Data dataset. These
reusable components are open and publicly available on
GitHub [58].
The RDF schema is a common data schema for all
national drug data repositories, used for modeling of drug
products on a global scale (Fig. 2). Its goal is to provide
alignment of drug data from different sources, with dif-
ferent format and different levels of data granularity, in
order to enable simpler data exploitation. It is comprised
of classes and properties from the Schema.org vocabulary
[59], which is a novel approach in the drug data domain.
The CSV template represents the necessary formal tem-
plate for the data which is being prepared for transfor-
mation, i.e. the data which will be annotated with our
RDF schema. It contains 39 columns which represent
the different data fields needed from the source data for
the transformation process. They inlude the URI of the
drug, its brand name, generic name(s), manufacturer, ATC
code(s), active ingredient(s), strength, cost, license infor-
mation, etc. They are modelled to fit the RDF schema,
which encompasses all data necessary for high-quality
modeling of the domain.
The OpenRefine transformation script is a reusable
tool which helps automate the transformation process,
while ensuring compliance of the generated data with
the defined RDF schema and therefore provides aligned,
high-quality 5-star Linked Data for the drug domain. Its
intent is to lower the bounds of transforming data into
RDF and Linked Data for data publishers which are not
deeply involved and experienced in the Semantic Web
and Linked Data practices. Through several sub tasks,
this reusable script for the OpenRefine-based suite of
tools (e.g. LODRefine, BatchRefine), interlinks the drug
products between themselves based on the therapeutic,
pharmacological and chemical properties of the drugs,
links the drug products to generic drugs, i.e. active ingre-
dients from the LOD Cloud datasets and transforms the
data into RDF format.
The SPARQL-based tool for extending and interlink-
ing the dataset is comprised of two reusable SPARQL
queries. The first query extends the dataset by assigning
ATC codes to all drugs from the dataset which miss this
information. It does so by using the interlinked nature of
the dataset, i.e. the links the drug products have to generic
drugs and active ingredients from the LOD Cloud. The
second query detects all pairs of drugs from the dataset
which have the same ATC code, and then interlinks them
with properties from the RDF schema which denote the
therapeutic, pharmacological and chemical similarity of
the drugs.
The web-based tool for automated transformation,
interlinking and publishing of the generated Linked Drug
Data dataset is intended for data publishers which gen-
erate Linked Drug Data with the previous tools. The
data publishers can upload the generated Linked Data
dataset(s) on the LinkedDrugs project website [60], and
after a human-based quality assessment, the dataset will
be automatically published. For this we use a publicly
available Virtuoso instance [61], from which the new
dataset is available on the Web as Linked Data, via its
SPARQL endpoint [62].
LinkedDrugs: global linked drug products dataset
We applied the outlined steps of the methodology and
the set of tools as part of an automated system for
transforming and generating 5-star Linked Drug Data
from twenty-three countries: Austria, Azerbaijan, Costa
Rica, Cyprus, Egypt, Estonia, Ireland, Macedonia, Malta,
Jovanovik and Trajanov Journal of Biomedical Semantics  (2017) 8:3 Page 6 of 24
Fig. 2 The RDF vocabulary designed for the drug data domain, comprised of Schema.org classes and properties. For dataset interoperability, it also
uses the classes from the ATC Classification Ontology and properties from the DrugBank Ontology and RDFS
Netherlands, New Zealand, Nigeria, Norway, Romania,
Russia, Serbia, Slovakia, Slovenia, South African Republic,
Spain, Uganda, Ukraine and USA. The countries were
chosen to represent the global diversity and to show that
a holistic solution for generating Linked Drug Data on a
global scale is possible. Currently, the generated Linked-
Drugs dataset contains over 99,000,000 RDF triples, which
represent data for over 248,000 drug products from
the denoted countries. The dataset also contains over
91,000,000 schema:relatedDrug relations between
the drugs, and over 278,000 rdfs:seeAlso relations to
generic drugs from DrugBank and DBpedia.
This automated system and its workflow represent a
concrete example of applying the methodological guide-
lines and supporting tools presented in this paper, and
thus serve as their validation scenario.
Generating the LinkedDrugs dataset
The national drug registries of many countries around
the world are available online. We analyzed the national
drug registry websites of 31 countries in order to define a
common set of properties, i.e. a schema skeleton, for the
target dataset. These steps of domain analysis and RDF
schema definition correspond to the activities denoted in
Step I and Step II of the methodological guidelines, which
are already done and we directly use them for our specific
application.
In order to design, test and validate our automated sys-
tem for gathering 2-star drug data from the national drug
registries and generating 5-star Linked Data from the drug
domain on a global scale, we selected a subset of twenty-
three countries. We aimed for a diverse subset, which will
encompass different global regions.
The drug registries of these countries are available
online. Their websites are listed in the project page on
GitHub [58]. The drug data from most of the national
registries is available in a structured format in HTML
pages, intended for human consumption via searching
and browsing on the website itself. The data from a
smaller group of countries is available via structured files
in Microsoft Excel or PDF formats, available for direct
download.
The automated system gathers the data, performs data
cleaning, aligns the data with the predefined schema
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skeleton, uses the transformation script and the SPARQL
query to transform the data to RDF, extend it with missing
ATC codes and add links to drugs from the same dataset
and drugs from DrugBank and DBpedia, thus turning
the dataset into a Linked Data dataset. The workflow of
these actions is depicted in Fig. 3. These steps represent
the activities defined in Step III of the methodological
guidelines.
Data gathering and staging. In order to create a sus-
tainable system for Linked Drug Data, we had to design a
way to collect the necessary data from the national drug
registries, on a scheduled basis. Therefore, we developed
a set of specialized web crawler applications which crawl
the designated drug registry websites, collect the neces-
sary data, clean it and store it in a predefined CSV format
(Fig. 3). We need to use a set of such crawlers as the target
websites differ in structure and available data. The out-
put CSV files from the crawlers use the predefined CSV
structure described above.
Like most of the data available on the Web, the drug
data available on the national drug registry websites is
not evenly structured, nor completely clean. We therefore
needed to extend our crawlers with functionalities which
perform data cleaning tasks and work to detect data from
all variations of the source webpages.
As per the suggestions in Step III of the guidelines,
we used their existing webpage URLs of the drugs as
their unique URIs, e.g. https://lekovi.zdravstvo.gov.mk/
drugsregister/detailview/53457. As many of the drug enti-
ties contain information about more than one generic
name, manufacturer, active ingredient and strength, the
crawlers are tasked with splitting them into the corre-
sponding columns in the CSV files. Additionally, infor-
mation such about the cost of the drug and its strength
are split into separate fields, to match the CSV template.
The crawlers also take care about the specific formats
needed for some of the columns, such as the dates, the
country codes, the currency codes, and the prescription
status.
The drug data from the several of the countries were
an exception, as they are available for download as
Microsoft Excel or PDF files. For these datasets, the
crawlers have to restructure the columns from the source
data and generate a CSV file with the correct column
names according to the CSV template. For these drugs,
we generate custom URIs as identifiers, which have the
format http://linkeddata.finki.ukim.mk/lod/data/loddw/
drugs/countryCode#drugID. Here, drugID is an ID gen-
erated by the crawler, countryCode is a three-letter
country code (according to [63]) of the country where the
drug was registered and the other parts of the URI identify
the project and the datatype on our Linked Data website:
/lod/data/loddw is the project and /drugs is the
categorization of the data.
The result of this stage in the workflow, in our case with
the twenty-three selected countries, is a set of twenty-
three separate CSV files which follow the CSV template.
The only difference is that some of the CSV files can have
no values in some columns, due to the data being unavail-
able online. When we get all twenty-three CSV files, the
first part of the workflow is done andwe can continue with
the second part.
Transformation to Linked Data. The CSV files can
be combined into one CSV file, or remain separate. The
only difference will be in the performance of the next
step which can be done as a single longer process, or
as twenty-three separate and shorter processes. To keep
the processing time per transformation shorter, we use
twenty-three separate CSV files, each representing the
drug dataset of a different country.
We send the twenty-three CSV files to a BatchRe-
fine instance [64], which represents a wrapper over an
Fig. 3Workflow: Transforming 2-star data from different national drug data registries to 5-star Linked Drug Data
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OpenRefine instance with the RDF extension, that can
be used as a REST-based service. The HTTP POST calls
to the BatchRefine REST-based service are done with the
reusable BASH script developed as part of the methodol-
ogy supporting tools and contain (a) the CSV file which
needs to be transformed and (b) the OpenRefine trans-
formation script defined as a supporting tool for the
guidelines. The result of the call is a transformed RDF out-
put, which contains part of the generated Linked Drug
Data dataset.
The output of our BatchRefine transformations are
twenty-three RDF files in Turtle format. These RDF files
are a Linked Data dataset: they contain 5-star data about
the drugs from the twenty-three countries, along with
links to generic drugs from the LOD Cloud - more specif-
ically, links to generic drugs from both DBpedia and
DrugBank. As we will see later in the text, we can use these
links to fetch data about the drugs from our dataset which
we don’t have on our end and which do not exist on the
source national drug registry websites, but can be found
in other datasets on the Web and can potentially prove to
be of interest for the end-users.
After the transformation with BatchRefine is done, we
load the RDF files into a Virtuoso instance [61] using a
BASH script. All RDF files are loaded into the same RDF
graph. The latest run of the workflow (Fig. 3) resulted in
248,746 distinct drugs in this step, represented with a total
of 7,245,294 RDF triples and with 278,542 outgoing links
to drugs from the LOD Cloud.
After the RDF data has been stored into an RDF graph
in Virtuoso, we use the SPARQL queries for extend-
ing the dataset with missing ATC codes and interlink-
ing related drugs. We execute the SPARQL queries over
our dataset stored in Virtuoso, using a BASH script.
In the latest run of the workflow (Fig. 3), 38,758 new
ATC codes were added for drug products which did
not have an ATC code in the source registry. Then,
91,782,500 schema:relatedDrug triples were added
between similar drug products, i.e. 45,891,250 pairs of
drugs from our dataset were identified to have the same
function, but exist under different brand names, are from
different countries, or are produced by different manufac-
turers, or maybe have a different packaging size, strength,
cost, etc. As we will see further in the text, we can utilize
these interlinkings for providing the users with alternative
drugs they may aquire for treating their condition, either
in the same of in a different country.
The workflow shown in Fig. 3 is activated on a sched-
uled period, currently set at one month. In order to handle
the data changes during updates, we backup the RDF
graph holding our dataset and replace it with the newly
created RDF graph. With this we employ versioning and
maintain the default graph identifier to always denote the
latest version of the LinkedDrugs dataset.
According to the recommendations in Step IV of
our guidelines, the dataset needs to be published on
the Web, where it will be publicly available. There-
fore, we published our LinkedDrugs dataset accord-
ing to the best practices for publishing Linked Data
[50], via a permanent, dereferenceable URI, which sup-
ports HTTP content negotiation: http://linkeddata.finki.
ukim.mk/lod/data/drugs# [65]. The dataset is hosted
at a live Virtuoso instance [61], in a named RDF
graph <http://linkeddata.finki.ukim.mk/lod/data/drugs#>
which holds the latest version of the dataset, publicly
available via a SPARQL endpoint [62] which serves as
a REST-based service. Additionally, data dumps of the
dataset are available on Datahub [55].
Usage scenarios
With the automated system and its workflow we start
with twenty-three different, distributed and browsable
datasets, available on the Web and intended for human
consumption via HTMLwebpages, and using themethod-
ological guidelines and tools we manage to create a con-
solidated dataset of interlinked and schema-aligned drug
products from different countries, additionally linked to
generic drugs and active ingredients from the LODCloud.
In order to demonstrate the advantages of having the drug
data in a 5-star data quality format, and therefore imple-
ment the recommendations from Step V of the method-
ological guidelines, we will show a few use-case scenarios
via SPARQL queries. The most basic scenario would be to
select all data about a single drug of interest, which is very
simple and straight-forward, and therefore omitted here.
Since the Virtuoso SPARQL endpoint at [62] can be used
as a REST-based service, these SPARQL queries could be
used from any type of application to always access and
exploit the latest data available.
Interlinked drug data. The interlinking cre-
ated between the drugs from the dataset, with the
schema:relatedDrug triples, can be utilized in a
use-case which allows the end-users to discover drugs
from the same country or another country which have
the same therapeutic, pharmacological and chemical
properties as the drug of his/her interest. This is a useful
feature when the drug of interest is not available or when
the user is traveling abroad. Getting information about
drugs with the same properties and their respective prices
can be useful for determining the drug from a specific
category which is affordable in the specific case. This can
be used by pharmacists, doctors and even patients for
gathering information and determining the appropriate
treatment.
An example SPARQL query which can be used to iden-
tify the drugs from all countries which have the same
therapeutic, pharmacological and chemical properties as
the drug of interest, is shown below (Query 1).
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Query 1
1 prefix schema: <http://schema.org/>
2 prefix drugbank: <http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/>
3
4 SELECT ?drug ?name ?gtin ?strengthValue ?strengthUnit ?costPerUnit





10 schema:relatedDrug ?drug .
11 OPTIONAL { ?drug schema:name ?name }
12 OPTIONAL { ?drug schema:gtin13 ?gtin }
13 OPTIONAL { ?drug schema:prescriptionStatus ?prescriptionStatus }
14 OPTIONAL { ?drug schema:addressCountry ?country }
15 OPTIONAL {
16 ?drug schema:cost ?costEntity .
17 ?costEntity schema:costPerUnit ?costPerUnit ;
18 schema:costCurrency ?costCurrency .
19 }
20 OPTIONAL {
21 ?drug schema:availableStrength ?strengthEntity .
22 ?strengthEntity schema:strengthValue ?strengthValue ;
23 schema:strengthUnit ?strengthUnit .
24 }
25 OPTIONAL {
26 ?drug schema:manufacturer ?manufacturerEntity .
27 ?manufacturerEntity schema:legalName ?manufacturerName .
28 }
29 }
30 ORDER BY ?name
In the query, only a handful of data of interest of the
related drugs are selected, but depending on the specific
use-case, they can be expanded. Query 1 can also be mod-
ified to include the specific drug of interest, by modifying
the drug URI in line 8. In our example in Query 1, we
use the Norwegan drug “Airomir” as an example, and get
results for over 300 distinct and related drugs from many
different countries in the dataset. The query and its full
results can be viewed online on Seminant [66], at http://
seminant.com/queries/5803e77573656d19eb6c5d00. Par-
tial results are shown in Table 1.
Linked LOD drug data. The main advantage of hav-
ing links between data from different and distributed
datasets is the ability to query them from a sin-
gle point, over the existing infrastructure of the Web,
using W3C standards such as HTTP, SPARQL and
RDF. As we have rdfs:seeAlso links from drugs
in our dataset to corresponding generic drugs from
the DrugBank and DBpedia datasets, we can utilize
them to get additional information about the drugs
from our dataset whenever we are browsing them.
Such additional information will come from the Drug-
Bank and DBpedia datasets, and can include additional
drug description, the interactions the drug has with
other drugs or with certain foods, the drug mech-
anism of action, the drug pharmacology, absorption,
biotransformation and toxicity, the list of alternative
brand names and a list of webpages for the drug on other
locations on the Web. This data is not available on the
original national drug registry websites, which are the
source for our dataset; it is data retrieved directly from
the distributed DrugBank and DBpedia dataset, using
SPARQL federation [67].
An example of a federated SPARQL query which selects
information about a drug of interest from the DrugBank
and DBpedia datasets is shown below (Query 2).
Table 1 Partial results from Query 1
Drug product Manufacturer Country






Aeroline 400 Inhaler EG
Aerotropa Pharco B International-egpyt EG




Airomir Autohaler Teva Sweden AB NO





Teva Pharma S.L.U. ES
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Query 2
1 prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#>
2 prefix schema: <http://schema.org/>
3 prefix drugbank: <http://wifo5-04.informatik.uni-mannheim.de/drugbank/
4 resource/drugbank/>
5 prefix dbo: <http://dbpedia.org/ontology/>
6 prefix dbp: <http://dbpedia.org/property/>
7
8 SELECT ?loddrug ?genericName
9 (group_concat(distinct ?brandName; separator = ", ") AS ?brandNames)
10 ?comment ?description ?biotransformation ?affectedOrganism ?absorption
11 ?chemicalFormula ?toxicity
12 (group_concat(distinct ?foodInteraction; separator = " ") AS ?foodInteractions)
13 (group_concat(distinct concat(?interactingDrugLabel, ‘: ’, ?interactionStatus);
14 separator = ". ") AS ?drugInteractions)
15 (group_concat(distinct ?url; separator = ", ") AS ?urls)
16 WHERE {
17 GRAPH <http://linkeddata.finki.ukim.mk/lod/data/drugs#> {
18 <http://www.aemps.gob.es/cima/especialidad.do?metodo=
19 verPresentaciones&codigo=79539>
20 rdfs:seeAlso ?loddrug .
21 }
22 SERVICE <http://wifo5-04.informatik.uni-mannheim.de/drugbank/sparql> {
23 OPTIONAL { ?loddrug drugbank:description ?desc . }
24 OPTIONAL { ?loddrug drugbank:genericName ?gname . }
25 OPTIONAL { ?loddrug drugbank:brandName ?bname . }
26 OPTIONAL { ?loddrug drugbank:biotransformation ?biotransformation . }
27 OPTIONAL { ?loddrug drugbank:affectedOrganism ?affectedOrganism . }
28 OPTIONAL { ?loddrug drugbank:absorption ?absorption . }
29 OPTIONAL { ?loddrug drugbank:chemicalFormula ?chemicalFormula . }
30 OPTIONAL { ?loddrug drugbank:foodInteraction ?foodInteraction . }
31 OPTIONAL { ?loddrug foaf:page ?page . }
32 OPTIONAL { ?loddrug drugbank:toxicity ?toxicity . }
33 OPTIONAL {
34 ?drugInteractionEntity drugbank:interactionDrug1 ?loddrug ;
35 drugbank:interactionDrug2 ?interactingDrug ;
36 drugbank:text ?interactionStatus .
37 ?interactingDrug rdfs:label ?interactingDrugLabel .
38 }
39 }
40 SERVICE <http://dbpedia.org/sparql> {
41 OPTIONAL {
42 ?loddrug dbo:abstract ?abstract .
43 FILTER (langMatches(lang(?abstract), "en"))
44 }
45 OPTIONAL {
46 ?loddrug rdfs:label ?label .
47 FILTER (langMatches(lang(?label), "en"))
48 }
49 OPTIONAL {
50 ?loddrug rdfs:comment ?comment .
51 FILTER (langMatches(lang(?comment), "en"))
52 }
53 OPTIONAL { ?loddrug dbp:tradename ?tradename . }
54 OPTIONAL { ?loddrug dbo:wikiPageExternalLink ?externalLink . }
55 }
56 BIND(IF(bound(?abstract), ?abstract, ?desc) as ?description)
57 BIND(IF(bound(?bname), ?bname, ?tradename) as ?brandName)
58 BIND(IF(bound(?gname), ?gname, ?label) as ?genericName)
59 BIND(IF(bound(?page), ?page, ?externalLink) as ?url)
60 }
The query selects some very important data about the
drug of interest and its active ingredient from Drug-
Bank and DBpedia. The most significant are the chemical,
biological and pharmacological properties of the drug,
along with its interactions with food and with other drugs.
This data is not always available on the national drug data
registries, but is of high importance for the end-users,
especially the pharmacists and doctors who may require
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Table 2 Partial results from Query 2
Description (from DBpedia)
Duloxetine (Cymbalta, and generics) is a serotonin-norepinephrine reuptake inhibitor (SNRI) created by Eli Lilly. It is mostly prescribed for major depres-
sive disorder, generalized anxiety disorder, fibromyalgia and neuropathic pain. Duloxetine failed to receive US approval for stress urinary incontinence
amid concerns over liver toxicity and suicidal events; however, it was approved for this indication in the UK, where it is recommended as an add-on
medication in stress urinary incontinence instead of surgery.
Food Interactions
Food does not affect maximum levels reached, but delays it (from 6 to 10 hours) and total product exposure appears to be reduced by only 10 percent.
People taking this product who drink large amounts of alcohol are exposed to a higher risk of liver toxicity. Take without regard to meals.
Drug Interactions
Amitriptyline: Possible increase in the levels of this agent when used with duloxetine.
Ciprofloxacin: Ciprofloxacin increases the effect/toxicity of duloxetine.
Desipramine: Possible increase in the levels of this agent when used with duloxetine.
Flecainide: Possible increase in the levels of this agent when used with duloxetine.
Fluvoxamine: Fluvoxamine increases the effect and toxicity of duloxetine.
Imipramine: Possible increase in the levels of this agent when used with duloxetine.
Isocarboxazid: Possible severe adverse reaction with this combination.
Nortriptyline: Possible increase in the levels of this agent when used with duloxetine.
Phenelzine: Possible severe adverse reaction with this combination.
Propafenone: Possible increase in the levels of this agent when used with duloxetine.
Rasagiline: Possible severe adverse reaction with this combination.
Thioridazine: Increased risk of cardiotoxicity and arrhythmias.
Tranylcypromine: Possible severe adverse reaction with this combination
them when determining treatment for acute conditions
of a patient who is already on a treatment of a chronic
medical condition.
An example run of Query 2, for the drug prod-
uct “Duloxetina” from Spain, results in details for
the generic drug “Duloxetine” from both Drug-
Bank and DBpedia: http://seminant.com/queries/
5803e9b973656d19eba65e00. Among other details, it also
shows the 3 specific food - drug interactions the drug
is involved in, along with the 13 drug - drug interac-
tions it has. Partial results from the query are shown in
Table 2.
Analytics. Aside from the use-case scenarios for end-
users, our LinkedDrugs dataset can be used for analytical
queries as well. These analytical queries allow interested
parties to gain insight into the drug markets of different
countries, allowing them to analyze the available consol-
idated data using a single entry point for querying and
using a single query language. The analytics could be built-
in in specific analytic applications, or can be executed with
separate and standalone SPARQL queries.
To get a better understanding of the analytical possibil-
ities over consolidated drug data from multiple countries,
we will look at an example query which identifies the most
common drug categories per country. This would allow
the user, e.g. pharmaceutical company, to gain a better
knowledge on the national drug markets and make an
informed decision about placing their drug in the country
of interest. A general SPARQL query for this analytical
scenario is given below (Query 3):
Query 3
1 prefix schema: <http://schema.org/>
2 prefix drugbank: <http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/>
3
4 SELECT count (distinct ?drug) as ?count ?atc ?country
5 FROM <http://linkeddata.finki.ukim.mk/lod/data/drugs#>
6 WHERE {
7 ?drug a schema:Drug ;
8 schema:addressCountry ?country ;
9 drugbank:atcCode ?atcCode .
10 FILTER (strlen(?atcCode) > 3)
11 BIND(SUBSTR(xsd:string(?atcCode), 1, 3) AS ?atc)
12 }
13 GROUP BY ?country ?atc
14 ORDER BY DESC (?count)
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Table 3 Partial results from Query 3










A sample run of Query 3 shows that Romania, Spain,
Netherlands, Ireland and Slovakia have most drugs (5,362,
2,152, 1,488, 758 and 709, respectively) in the category
of agents acting on the renin-angiotensin system (ATC
C09), Russia and South African Republic have most drugs
(1,536 and 976, respectively) in the category of antibac-
terials for systemic use (ATC J01), while USA has 1,270
drugs in the psycholeptics category (ATC N05). These
partial results are shown in Table 3. The full results from
the query are available at http://seminant.com/queries/
5803ebc473656d19ebac5e00.
Another analytical scenario would be to assess the aver-
age drug price per drug category, per country. It could be
used by medical authorities in a country to determine the
cost situation per category in other countries and use the
information for local regulations. It could also be used by a
pharmaceutical company to determine the price range for
a new drug, before it goes to market. An example SPARQL
query which can be used for such an analysis is given
below (Query 4):
A sample run of Query 4 identifies that the ATC drug
categories with the highest average price in Norway are
drugs for disorders of the musculo-skeletal system (ATC
M09), respiratory system products (ATC R07) and ali-
mentary tract and metabolism products (ATC A16). In
Macedonia they are alimentary tract and metabolism
products (ATC A16), pituitary and hypothalamic hor-
mones and analogues (ATC H01) and antihemorrhagics
(ATC B02), while in Australia and Slovenia they are respi-
ratory system products (ATC R07) and in South African
Republic they are immunosuppressants (ATC L04), hema-
tological agents (ATC B06) and alimentary tract and
metabolism products (ATC A16). These partial results are
shown in Table 4, while the full results which include other
countries as well, are available at http://seminant.com/
queries/5803ed6e73656d19eb537e00.
In cases when an inter-country comparison of the pric-
ing is necessary, an application could use a currency
converter to transform the values to the same currency of
choice, and make the comparison.
Discussion
The generated LinkedDrugs dataset aims to be the first
comprehensive, consolidated and aligned dataset of drug
product data on a global scale. In its first version, the
dataset consisted of only seven countries; currently, that
number has grown to twenty-three. As we have the
methodology and the tools in place, the addition of new
countries is more or less straightforward. Even though
Linked Data datasets with drug data already exist in the
LOD Cloud, they consist solely of generic drugs, i.e. active
ingredients. Contrary to this, our LinkedDrugs dataset
consists of drug products which are registered in a specific
Query 4
1 prefix schema: <http://schema.org/>
2 prefix drugbank: <http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/>
3
4 SELECT (?totalCost / ?drugCount as ?averageCost) ?costCurrency ?atc
5 ?drugCount ?country
6 WHERE {
7 SELECT count (distinct ?drug) as ?drugCount
8 sum (xsd:float(?cost)) as ?totalCost
9 ?costCurrency ?atc ?country
10 FROM <http://linkeddata.finki.ukim.mk/lod/data/drugs#>
11 WHERE {
12 ?drug a schema:Drug ;
13 schema:addressCountry ?country ;
14 drugbank:atcCode ?atcCode ;
15 schema:cost ?costEntity .
16 ?costEntity schema:costPerUnit ?costPerUnit ;
17 schema:costCurrency ?costCurrency .
18 FILTER (strlen(?atcCode) > 3)
19 BIND(SUBSTR(xsd:string(?atcCode), 1, 3) AS ?atc)
20 FILTER (?costPerUnit != "0"^^xsd:double)
21 BIND(REPLACE(?costPerUnit, ",", ".") AS ?cost)
22 }
23 }
24 GROUP BY ?country ?atc ?costCurrency
25 ORDER BY DESC (?averageCost)
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Table 4 Partial results from Query 4
Avg. price Currency ATC Prefix Country
93480.60 NOK M09 NO
47221.40 NOK R07 NO
39557.30 NOK A16 NO
32021.40 MKD A16 MK
28837.20 MKD H01 MK
27478.20 MKD B02 MK
22500.00 AUD R07 AU
17822.00 SVN R07 SI
13360.10 EUR V10 CY
10679.50 ZAR LO4 ZA
10127.10 ZAR B06 ZA
9880.81 ZAR A16 ZA
country, have a specific name, dosage form, amount,
strength, barcode, manufacturer, license, price, ATC code,
etc. Since these drug products from our dataset are linked
to the existing generic drugs and active ingredients from
the LOD Cloud, the novel usage scenarios greatly exceed
what is currently possible with Linked Drug Data on
the Web.
The developed methodological guidelines and support-
ing tools intend to encourage and lower the boundaries
for data publishers from the domain to contribute to
the LinkedDrugs dataset, further extending its potential
and value. Since the adoption of the developed tools can
present a potential hurdle, we believe that the transfor-
mation process presented in this paper can serve as an
additional guide.
Our methodological guidelines extend the existing
Linked Data methodologies, briefly presented in the
section “Background” . Here, we will make an explicit
comparison of the similarities and differences in the
approaches among the existing methodologies, and our
findings and proposal to group them into five gen-
eral steps. These five general steps have allowed us to
define our own methodological guidelines for the drug
data domain, by defining tasks and tools specific for the
domain and adding them to the corresponding general
steps. These specific tasks and tools have been the result
of our research in the domain, as well as our previous work
with generating, publishing and using healthcare Linked
Data datasets.
The existing Linked Data methodologies have a vary-
ing number of steps, but still generally cover the same
activities. The main difference in the methodologies is the
grouping of actions within different steps and on different
levels of granularity. Apart from some explicit differences,
which we will further examine, they cover the palette of
actions involved in the process of generating and publish-
ing a Linked Data dataset, and thus can be grouped into
five general steps.
From Table 5, we can see that all existing Linked
Data methodologies define the knowledge of the data, its
domain and the existing datasets from the LOD Cloud as
the first step(s). The actions they cover in the steps relate
to these tasks, and while somemethodologies focus on the
data domain, others recommend knowledge of existing
Linked Data datasets, as well.
The second step refers to the tasks of modeling the data,
locating and selecting the appropriate ontology or vocab-
ulary, extending existing ontologies and vocabularies to
Table 5 Aligning our methodological guidelines with existing Linked Data methodologies. Additionally, our approach focuses on
lifecycle reuse by step modularity
Our Methodology Hyland et al. Hausenblas et al. Villazón-Terrazas et al. LOD2
I. Domain and Data Knowledge 1. Identify 1. Data Awareness 1. Specify 1. Extraction
2. Storage
II. Data Modeling and Alignment 2. Model 2. Modeling 2. Model
3. Name
III. Transformation into 5-star Linked Data 4. Describe 3. Publishing 3. Generate 3. Authoring
5. Convert 4. Discovery 4. Interlinking
5. Integration 5. Classification
6. Quality
7. Evolution/Repair
IV. Publishing the dataset on the Web 6. Publish 4. Publish
V. Use-cases, Apps and Services 6. Use cases 5. Exploit 8. Search/
Browsing/
Exploration
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match the original data schema, creating a custom ontol-
ogy or vocabulary from scratch and mapping it to existing
ontologies, and defining the URI naming scheme for the
ontology classes and properties. The methodologies of
Hyland et al. [51], Hausenblas et al. [52] and Villazón-
Terrazas et al. [53] explicitly define these tasks, whereas
the LOD2 methodology does not define them. For this
step, we defined an RDF schema which can be reused
when working with drug data from national drug reg-
istries or other sources. The provided CSV template
allows the data publisher to align the data in the cor-
rect format in a CSV file, and prepare it for the next
step.
The third step is focused on transforming the source
data into RDF, creating links and 5-star Linked Data
datasets, and creatingmetadata descriptions of the dataset
and its links to other datasets. All four methodologies
define these tasks, with the LOD2 methodology being the
most specific one. The LOD2 methodology, being the lat-
est one, understandably contains activities which include
classification, quality control, data evolution and version-
ing. The use of the VoID vocabulary is explicitly stated
in this phase in the methodologies of Hyland et al. and
Hausenblas et al. The methodology of Villazón-Terrazas
et al. defines this task in its next step, ‘4. Publish’, but
as it contains other tasks which better fit in our next
step, we left it out of this one. Here, we developed an
OpenRefine transformation script which can be used with
any source drug data formatted with the CSV template
from the previous step, in order to get high quality, 5-star
Linked Drug Data. For the purpose of generating addi-
tional links between similar drugs in the dataset itself, we
developed a SPARQL-based tool which can be used over
any Linked Drug Dataset generated with the OpenRefine
transformation script.
The fourth step defines the tasks for publishing the
dataset on the Web. The exact actions which should be
undertaken are defined in the methodologies of Hyland
et al. and Villazón-Terrazas et al. The other two method-
ologies do not define such tasks and steps. In order to
simplify this step for data publishers, we provide a web-
based tool for automated publishing of the generated
Linked Drug Data dataset. The tool also interlinks the new
dataset with the consolidated LinkedDrugs dataset, which
already contains drug product data from twenty-three
national drug repositories.
The fifth step consists of tasks for defining use-case
scenarios or development of specific applications and ser-
vices which take advantage of the newly created Linked
Data dataset and its links to other datasets. Themethodol-
ogy of Hyland et al. does not specify such an activity, argu-
ing that the data publisher does not have to think about
potential use and reuse of the data while working on gen-
erating Linked Data from the source dataset. According to
them, the data publisher should just make sure he/she cor-
rectly transforms, describes and publishes the data, and let
the users and the interested community know about the
dataset. However, Hausenblas et al., Villazón-Terrazas et
al. and the LOD2 Project team explicitly state that the last
step of the Linked Data generation process should consist
of defining use-cases and/or developing applications and
services.
The tools we developed as support for the steps of
the methodology aim to help data publishers from the
domain. They can aid both data publishers from the drug
domain which do not necessarily have prolific experience
with Linked Data, as well as Linked Data publishers which
are not very familiar with the domain of drugs and health-
care. These open-source and reusable tools are supposed
to lower the bounds for interested parties to get involved
in the domain and include their datasets in the global
LODD and LOD Cloud.
Conclusions
The amounts of data available on the Web represent
a goldmine for data-driven applications and services
[68]. Unfortunately, the data is available in different for-
mats and is distributed over various locations. This is
a huge obstacle which blocks progress in data retrieval
in many domains. The healthcare domain is no differ-
ent: the national drug authorities publish their data on
the Web in different formats and granularity levels, and
there is no comprehensive method for retrieving and
using them.
The Linked Data concept provides new ways of pub-
lishing and connecting data from different distributed
sources, which allows data consolidation. It also pro-
vides a new spectrum of use-case scenarios which can
be useful for generating new business value for busi-
nesses and independent developers, by allowing them
to develop innovative applications and services in the
domain. The opportunities which lie within the creation
of new use-case scenarios from Open Data and Linked
Data are a field whose potential is becoming increasingly
recognized [69].
Motivated by this, we propose methodological guide-
lines for using Linked Data principles to consolidate
drug data, and provide a set of tools which intend to
aid the data publishers in the steps of the methodol-
ogy. Our methodological guidelines extend the existing
Linked Data methodologies, both general and aimed for
government data. We combine the steps from the exist-
ing methodologies into five steps which are necessary for
developing a sustainable Linked Data dataset. Each of
these steps is extended to include specific tasks, actions
and tools which are important for the drug data domain.
The aim of our methodological guidelines is to enable the
creation of Linked Drug Data datasets which are very well
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aligned between themselves and which can then easily be
consolidated into a comprehensive system or dataspace.
We implemented our guidelines and tools as part of
an automated system for transformation and publish-
ing of the 2-star and 3-star data from twenty-three
national drug registries into consolidated and aligned
5-star Linked Drug Data. The system provides reg-
ular updates which make sure the created Linked-
Drugs dataset always contains new data. In order to
create the dataset, we use the defined common RDF
schema, the CSV template, the OpenRefine transforma-
tion script, as well as the SPARQL queries for extending
the dataset and interlinking the drugs from the dataset.
With this, we ensure data alignment with other LOD
and LODD datasets. Currently, our generated Linked-
Drugs dataset contains over 99,000,000 RDF triples, which
represent data for over 248,000 drug products from
twenty-three countries. The dataset also contains over
91,000,000 schema:relatedDrug relations between
the drugs, and over 278,000 rdfs:seeAlso relations to
generic drugs and active ingredients from DrugBank and
DBpedia.
We further present new usage scenarios enabled by
Linked Data, aimed both for end-users and analytical pur-
poses, which utilize the consolidated and aligned nature
of the dataset and its contextual links to entities from the
LOD Cloud. We achieve this by automatically generat-
ing the additional relations in our dataset which link the
drugs between themselves, and link the drugs with drug
entities published as part of other LOD Cloud datasets.
Using W3C standards and the Semantic Web technolo-
gies, we are then able to retrive data from these distributed
datasets, and present them to the end-users in a compre-
hensive manner.
As future work, we plan to extend the number of
national drug registries from the current twenty-three.
The design of the supporting system requires that we only
modify the data gathering and staging part of the work-
flow, while the transformation and publishing process
remains the same. We also intend to extend the reconcil-
iation tasks in OpenRefine, by employing reconciliation
for the company names. This would provide additional
links in the dataset between the drugs and the manu-
facturers, represented by company entities on the LOD
Cloud. Given that the names of the companies and their
details are sometimes on local languages, depending on
the drug registry, we would also add a translation ser-
vice in the workflow. We also plan to add an automated
VoID metadata generation task for the dataset, which
is a recommendation from Step III. Regarding applica-
tions built on top of the datasets, we have already started
developing user-focused and analytical applications which
provide the end-users with detailed information about a
drug product and its interaction with other drugs and
foods, but also provide insight into the drug product avail-
ability on a global scale. All of these additional features
would further add to the benefit of having consolidated
and aligned drug data from various countries in one place,
accessible via the existing infrastructure of the Web and
via existing W3C standards.
Methods
Themethodological guidelines
Based on our experience with applying the Linked Data
principles in the healthcare and drug domain and on
the existing Linked Data methodologies, we developed a
set of methodological guidelines for consolidating drug
data using the Linked Data approach. These guidelines
improve upon the existing Linked Data methodologies
and contain steps, activities and tools which are specific
to the drug data domain. Their purpose is to guide data
publishers through the process of generating high qual-
ity, 5-star Linked Data in order to interlink, align and
consolidate drug data from different national drug reg-
istries or other sources of drug data. The alignment and
relationship between the existing methodologies and our
guidelines is outlined in Table 5.
Along with the guidelines, we have developed a set
of tools which simplify the execution of the specific
steps of the methodology. Their intention is to support
the Linked Drug Data generation process for both peo-
ple from the drug domain which do not have deeper
knowledge of Linked Data, and Linked Data publish-
ers which do not have deeper knowledge of the drug
domain. These tools are open and publicly available on
GitHub [58].
Our methodological guidelines consist of the following
steps (Fig. 1):
I. Domain and Data Knowledge
II. Data Modeling and Alignment
III. Transformation into 5-star Linked Data
IV. Publishing the Linked Data dataset on the Web
V. Use-cases, Applications and Services
These steps have been developed with reuse as a pri-
mary goal; therefore, their main focus is the encourage-
ment of data publishers in the drug domain to develop,
modify and use reusable components during the steps
of the methodology. This makes the Linked Drug Data
lifecycle modular, i.e. constructed of loosely-coupled
components which can be reused in the domain. These
loosely-coupled components can be used separately when
necessary, but also form a seamless workflow for generat-
ing a high-quality, 5-star Linked Drug Data dataset. The
reuse of such components, like in other software devel-
opment cases, reduces development time and increases
productivity [56, 57].
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Step I: Domain and data knowledge
The first step corresponds to the first steps from the exist-
ing methodologies: it is important for the data publisher
to know the domain and the data in it very well. This
understanding of the data source schema and semantics
is crucial for the following steps which will involve data
modeling, schema alignment and data transformation.
In the drug data domain, if this is the first time the data
publisher comes across Linked Data, our advice is to first
get familiar with the 5-star data system fromTim Berners-
Lee [35], the four principles of Linked Data [70], and the
LOD Cloud [32]. After that, a study of the LODD Project
[36], the Bio2RDF Project [43] and the DrugBank Linked
Data dataset [44] is recommended. This will help the data
publisher to get a better insight into the Linked Drug Data
and Linked Healthcare Data domains, the types of data
which exist in them, their schema, their similarities and
differences and their existing and potential links. It will
also help him/her determine the ontologies and vocabu-
laries already used in the domain, which can be important
for the next step.
In a general case, when working with any other domain,
it is important for the data publisher to get familiar with
the domain in question and with the meaning of the
dataset selected for transformation. For this, a consult
with a domain expert is usually necessary and there-
fore advised. Another approach is to explore the existing
Linked Data datasets which are similar to or from the
same domain as the one of interest. For this, the Datahub
portal [71] and the LOD Cloud cache instance [72] could
be used.
Step II: Datamodeling and alignment
In the next step, the data publisher should focus on data
modeling and alignment with other existing or future
datasets. The data publisher has to choose the correct
schema for the dataset, in order to annotate it correctly,
i.e. use the data fields which are necessary for the final
use-cases, annotate the fields unambiguously and with the
correct semantics and make the correct schema choices
which will allow seamless alignment with other datasets.
Additionally, the data publisher has to define the URI
naming scheme for the data entities, and optionally for the
ontology or vocabulary classes and properties.
Data schema. In the drug data domain, studying the
datasets from the LODD and Bio2RDF projects can help
get an insight into the ontologies and vocabularies used
in the domain. Some of the ontologies and vocabular-
ies which a data publisher needs to have in mind are:
Schema.org [59], DBpedia Ontology [73], UMBEL [74],
DICOM [75], the DrugBank Ontology used for the data at
[44], as well as other biomedical ontologies [76].
In order to support the data publishers from the
drug domain in this step, we designed a reusable RDF
schema for the data, shown in Fig. 2. The schema can
be used by data publishers working with drug data
from national drug registries or other sources. The
schema is comprised of classes and properties from
the Schema.org vocabulary [59]: the schema:Drug
class, along with a large set of properties which
instances of the class can have, such as name,
code, activeIngredient, nonProprietaryName,
availableStrength, cost, manufacturer,
relatedDrug, description, url, etc. Addition-
ally, in order to align the drug data with generic drugs
from DrugBank, we use the properties brandName,
genericName, atcCode and dosageForm from the
DrugBank Ontology. In order to annotate the links which
the drug product entities will have to generic drug enti-
ties from the LOD Cloud dataset, the rdfs:seeAlso
relation is used.
In general, when working with data from another
domain, the data schema is defined with the choice of
vocabularies or ontologies to be used. The principles of
ontology engineering and usage have been developed for
this purpose exactly: to maximise the chances of reuse,
and therefore allow better alignment between datasets
[77]. This means the agent should always try to reuse an
existing vocabulary or ontology, giving advantage to those
which are most widely used. A few tools for ontology and
vocabulary discovery exist, and the data publisher should
use them in this stage. The two most notable are Linked
Open Vocabularies (LOV) [78] and DERI Vocabularies
[79], which also provide usage statistics which can be used
to assess the impact of a given vocabulary or ontology in
a specific domain. Our choice of the Schema.org vocabu-
lary follows the reusability paradigm: it is the most widely
and generally used vocabulary across the Web.
However, datasets tend to have specific fields, which are
not covered by existing ontologies. In this cases, the exist-
ing ontology or vocabulary should be extended, or a new
one should be defined. However, each time a new ontol-
ogy is developed, it is important to define the mappings
between the new classes and properties and the classes
and properties from other ontologies, in order to enable
ontology matching and RDF-based reasoning, for schema
alignment. In order to avoid defining specific new prop-
erties, we reused some properties from the Schema.org
vocabulary which are currently not explicitly intended for
use with schema:Drug entities. An example of such
properties is the schema:addressCountry property
which should be used for an address, but we use it in
our schema to denote the country in which the drug is
registered.
Another important approach in this step is the use of
upper-level ontologies and vocabularies; they can pro-
vide a schema for many different and specific domains,
due to their generality. Having two or more datasets
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annotated with the same upper-level ontology or vocab-
ulary allows interlinking and inference between them,
i.e. it improves the alignment which is crucial for data
consolidation.
Data alignment. For the data alignment task, the data
publisher needs to make sure that the generated dataset
will be well aligned with existing and future datasets from
the same domain. In order to aid the data publishers with
this, as well as help them in preparing the drug data for
the transformation step, we developed a CSV template
intended for the drug domain [58]. This CSV template can
be used with the drug data and is comprised of the fields
necessary for applying the RDF schema from Fig. 2.
The data publisher interested in publishing Linked Drug
Data should use this CSV template for the data, following
the specifics defined for each of the fields. These specifics
assure that the data will be of high quality and completely
aligned with other drug data generated using the same
methodological guidelines.
URI formats. From the URI naming scheme perspec-
tive, in the domain of drug data it is important to deter-
mine the types of entities which exist in the dataset. This
will help in defining the entity URIs for the Linked Data
dataset. According to the Linked Data principles, each
entity in the dataset - along with the classes and proper-
ties in the ontology - needs to have a unique indentifier in
the form of an HTTP URI. In order to provide better per-
formance when using the dataset in the future, our experi-
ence suggests using separate URL paths for different entity
types, e.g. http://example.com/drug/, http://
example.com/interaction/, http://example.
com/disease/, etc. An additional recommendation is
to use slash-based URIs, instead of hash-based ones. This
may result in using an additional HTTP request by the
machine accessing the URI, but it provides better perfor-
mance when accessing large datasets [80].
However, to simplify this step for the drug data publish-
ers, we advise the use of the existing webpage URLs of
the drugs from the national registry websites, which are
already unique. According to the Linked Data principles,
the entity URI should denote a Web location where the
end-users and agents can get more information about the
entity, so our approach satisfies the condition.
Step III: Transformation into 5-star Linked Data
During the third step, the source dataset should be trans-
formed into a 5-star Linked Data dataset. The process of
transformation can be executed in many different ways,
and with various software tools, e.g. OpenRefine [81],
LODRefine [82], D2R Server [83], Virtuoso [84], Silk
Framework [85], etc.
To help the data publishers from the drug domain and
to automate this step, we developed a reusable OpenRe-
fine transformation script [58]. This transformation script
is specifically designed for the drug data domain, and the
RDF schema and CSV template from Step II. It contains a
set of actions which generate RDF from the inputed CSV
file which contains drug data. In the process, it also locates
associated generic drugs from the DrugBank and DBpe-
dia datasets for each drug product in source dataset, and
extends the generated RDF with links between the drugs
from the dataset and the corresponding drugs from the
LOD Cloud.
The transformation script can be reused with anyOpen-
Refine instance which has the RDF extension. It can be
applied on any drug data dataset formatted with the CSV
template from Step II. As a result, it will generate a Linked
Drug Data dataset annotated with the RDF schema from
Step II (Fig. 2).
The RDF schema from Step II defines relations between
the drug products from the dataset as well. These relations
are denoted with the schema:relatedDrug relation
(Fig. 2). In order to provide means for generating RDF
triples which interconnect the drugs from the dataset, we
developed a SPARQL query [58] which can be executed
over the dataset generated with the OpenRefine trans-
formation script. The SPARQL query detects all pairs of
drugs from the dataset which have the same ATC code
- and therefore have the same therapeutic, pharmaco-
logical and chemical properties - and creates two triples
connecting the first drug to the second one with the
schema:relatedDrug property, and vice-versa.
In a general case, in order to make the correct choices
about the tools to be used for the transformation pro-
cess, it is important to distinguish the characteristics of
the dataset first. The nature of the dataset will determine
if (a) the transformation is a one-time task, a task which
will have to be executed on a given time interval (e.g. once
a month), or a continually running task; (b) old versions
of the transformed dataset are necessary for versioning
and as backup, if during future transformations only the
changes in the data are needed for transformation, i.e.
‘delta’ updates are performed, or if older data are no longer
necessary for the particular use-case; (c) manual or auto-
mated data cleansing is needed before the first transfor-
mation and/or subsequent transformations; (d) the source
dataset is always available at the same location and is
accessible via the same interfaces. These specifics of the
dataset in question can then help the data publisher deter-
mine if the transformation task can be fully or partially
automated, and identify the parts of the transformation
workflow which require human attention and input.
Adding metadata about the newly created Linked Data
dataset is significant from the data reuse perspective -
using vocabularies such as VoID [86] help ubiquitously
determine the characteristics of the dataset and the links
the dataset has to other Linked Data datasets, through
software agents. VoID metadata contains information
Jovanovik and Trajanov Journal of Biomedical Semantics  (2017) 8:3 Page 18 of 24
about the name, description and category of the dataset,
versioning information and update frequency, contact
information, the license under which the dataset is made
available, the links to the SPARQL endpoints and URI
lookup endpoints, used vocabularies and their properties
and classes. It also explicitly defines the links between the
dataset and other Linked Data sets, defined in the dataset
itself. The use of the VoID vocabulary is explicitly stated in
the corresponding steps in the methodologies of Hyland
et al., Hausenblas et al. and Villazón-Terrazas et al.
In the domain of drug data providing new and updated
data is very important - old data has no importance
to the end-user, except for analytics. This means that
the data publisher should anticipate the change rate of
the source dataset and correctly design the workflow of
refreshing data from the source dataset to the Linked Data
dataset. This would translate to creating a sustainabil-
ity plan which will transform new data and add it to the
LinkedData dataset, remove old data and provide version-
ing. Depending on the size of the source dataset, the data
publisher can choose to re-transform the source dataset
on each update, or to provide means for performing ‘delta’
updates. Providing versioning is also important, as new
transformations can sometimes result in errors, rendering
the dataset unusable.
Step IV: Publishing the Linked Data dataset on theWeb
In the forth step, the generated 5-star Linked Data dataset,
along with its VoID metadata, should be published on the
Web. This should be done following theW3C recommen-
dations for publishing Linked Data on theWeb [50], which
suggest enabling direct URI resolution, providing a REST-
ful API, providing a SPARQL endpoint, and/or providing
the dataset as a file for download.
There is a large palette of tools and software platforms
which allow seamless Linked Data publishing. Among
them are D2R Server [83] and Virtuoso [84], which allow
Linked Data publishing of datasets which are originally
in an RDF file (Turtle, N3, RDF/XML, JSON-LD, etc.), a
CSV file, or in a relational database. These platforms then
allow access to the Linked Data dataset via HTML pages,
via RDF file downloads and via a SPARQL endpoint which
can be used as a RESTful API as well.
When creating a Linked Drug Data dataset, we
recommend adding and interlinking it with the global
LinkedDrugs dataset which will consist of all such
datasets generated by different parties, using these
guidelines. To enable this, we have developed a web-
based tool for uploading the generated datasets [60],
which after a human-based quality assessment triggers
an automated process for interlinking the new dataset
with the existing LinkedDrugs datasets and publishing
it according to the Linked Data principles and best
practices.
We also recommend publishing the dataset at
Datahub.io [71] under the healthcare and drugs
categories, as well as adding the #linkeddrugs tag.
Additionally, we advise joining the LOD Cloud [87]. Both
these actions will enable higher visibility of the dataset.
Another important part of this step is the announce-
ment of the newly created Linked Data dataset to the pub-
lic. For this, information about the dataset along with its
VoID metadata should be published on popular data por-
tals, such as Datahub.io [71]. This announcement should
also be done via existing communication channels of the
data publisher and his/her organization. In order to facil-
itate further use and reuse of the dataset, it is important
to provide a form or a contact email address for inter-
ested parties to be able to report data or access issues, and
provide feedback. On the organization side, it is impor-
tant that these reports and requests are attended to in
a timely fashion; otherwise the usability of the dataset is
significantly lowered.
Step V: Use-cases, applications and services
The last step refers to defining use-case scenarios and/or
developing specific applications and services which will
use the data from the newly created Linked Data dataset,
to showcase the (re)usability of the dataset and its links to
other Linked Data datasets. This will present the poten-
tial of the contextually linked datasets to future interested
parties.
When creating a Linked Drug Data dataset, poten-
tial use-case scenarios, applications and services should
include contextually linked data from the LODD datasets
and the Bio2RDF datasets. The LODD datasets, especially
the DrugBank linked dataset, contain data about generic
drugs, i.e. active ingredients, along with their pharma-
ceutical and pharmacological properties, targets, brand
names, food interactions, drug interactions, etc. Since the
national drug data registries contain information about
drug products, one-to-one mappings between the enti-
ties from such datasets and the DrugBank and DBpedia
datasets are not possible. Instead, using our RDF schema
from Step II and the OpenRefine transformation script
from Step III, each entity from the dataset will be linked to
one or more generic drugs/active ingredients from Drug-
Bank and DBpedia, based on its ATC code [88]. This
way, the drugs from the dataset get a contextual link to
the generic drugs, and from there, to all of its proper-
ties and characteristics. Additionally, the existing links
from the DrugBank and DBpedia generic drugs to other
healthcare datasets can be further exploited, as they also
represent contextual links. Such links currently point to
LinkedCT and Bio2RDF. To demonstrate the usability of
the generated Linked Drug Data datasets, we provide
example use-cases on the project website [60] and on
GitHub [58].
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In a general case, the use-cases can be text-based
scenarios, specific SPARQL queries, or prototype appli-
cations, describing the ways in which the data from
the new dataset can be browsed, retrieved and used.
Here, a specific focus should be given on how the
links to other Linked Data datasets can be exploited
to reach other data, not present in the original data
source, to extend its context. With this, the data pub-
lisher will show to interested parties that the original
dataset has more value when combined with datasets
from the same or similar context, instead of being used
in an isolated scenario. Besides such use-case, the same
effects of the Linked Data dataset can be showcased
with the development of applications and services. They
bring more visibility to the general (re)usability of the
Linked Data dataset, but generally require more time and
effort.
The created use-cases, applications and/or services,
should be shared and announced to the public, along with
the dataset itself and its VoID metadata. The use of the
same channels from the previous step is advised.
Methodology supporting tools
As part of the methodological guidelines, with the intent
to provide help to the data publishers working in the
drug data domain, we designed and developed a set
of tools. These tools consist of the RDF schema, the
CSV template, the OpenRefine transformation script, the
SPARQL-based tool for interlinking related drugs and the
web-based tool for automated transformation, interlink-
ing and publishing of the generated Linked Drug Data
dataset.
RDF schema
In order to model the domain of drug products on a global
scale, we needed to create one common schema for all
national drug data repositories, and then use it for anno-
tating the drug data. With it, the goal was to provide
alignment of drug data from different sources, with differ-
ent format and different levels of data granularity, in order
to enable simpler data exploitation.
First, we analyzed the national drug data repositories of
31 countries1 and the analysis helped us define a com-
mon set of properties which exist and which we want
to use in our dataset. This set consisted of 24 proper-
ties, including the brand name of the drug, the generic
name, the ATC code, the EAN code (barcode), the list
of active ingredients, the drug strength, dosage form,
cost, manufacturer, the country it was registered in, the
details about its license, etc. Not all national drug data
repositories provide all of the data and properties we
selected for our schema, but we did not want to decide
against using those properties - they are useful where
available.
Following the best practices in ontology and vocabulary
use [77], we started by considering reuse of classes and
properties from existing vocabularies. We used the com-
mon set of properties we defined in the previous step, and
found that the Schema.org vocabulary [59] was fully appli-
cable for our set. The Schema.org vocabulary, as part of its
Health and Lifesciences Extension [89], contains a defini-
tion of the class schema:Drug and contains a large set of
properties applicable to it [90]. As we can see on Fig. 2, the
RDF schema uses the DrugBank ontology and the RDFS
ontology, as well, for interoperability purposes.
Schema.org is a joint initiative of Google, Bing, Yahoo
and Yandex, as a common vocabulary intended for struc-
tured markup on web pages [91–93]. It is used by these
search engines to introduce rich snippets about people,
events, products, movies, restaurants, books, tv shows,
etc. It is also used in Google’s Knowledge Graph, in emails
confirming reservations and receipts (from restaurants,
hotels, airlines, etc.) both from Gmail and Microsoft’s
Cortana, it is used for rich pins on Pinterest, as well as
fromApple’s Siri [94]. Its use on theWeb has been increas-
ing in the past few years, more rapidly than the more rig-
orous general-purpose vocabularies and ontologies before
it [95]. Its success is mainly attributed to its simplicity:
it uses a generally flat hierarchy of classes, so that the
boundaries of implementation from data publishers and
webmasters is kept low.
The growing use of the Schema.org vocabulary, as well
as its domain generality, has put the vocabulary in a
position in which it is being used for aligning existing
ontologies and datasets. This is happening in the health-
care domain, as well [96]. With the release of Schema.org
version 3.0 [97], the medical and healthcare related terms
[98] have been moved to the Health and Livesciences
Extension [89], to enable and ensure future collabora-
tive development of the terms by the Healthcare Schema
Vocabulary community group at W3C [99, 100]. This
plan for a long-term support by the community from the
domain instills sufficient certainty for us to choose the
Schema.org vocabulary, instead of the domain specific
ontologies [76], to provide a common schema for drug
products on a global scale.
In order to provide some alignment between the gen-
erated datasets and the LODD and DrugBank datasets,
we use several properties from the DrugBank ontology
to describe the drug products. More specifically, we use
drugbank:brandName, drugbank:genericName,
drugbank:atcCode and drugbank:dosageForm
as additional properties for the same values denoted
by schema:name, schema:nonProprietaryName,
schema:code and schema:dosageForm, respec-
tively. We do this for simplifying the SPARQL federated
queries when working with data from our LinkedDrugs
dataset and the DrugBank dataset. Additionally, each drug
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product from the LinkedDrugs dataset is an instance of a
specific class from the ATC Classification Ontology [101],
in order to classify the drug according to the ATC classi-
fication system, based on its ATC code(s). We also chose
rdfs:seeAlso as it is the most widely used relation for
interlinking similar entities in the LOD Cloud [33].
Just as any other RDF schema, vocabulary and ontol-
ogy, the RDF schema selected for our Linked Drug Data
datasets can be evolve in time; it can be extended and
modified in the future by us or third-parties, as the field of
drug data evolves.
CSV template
In order to enable data publishers to annotate their drug
data with the RDF schema from Fig. 2, we need a for-
mal template for the data which is being prepared for
transformation, and a formal transformation process. For
the former, we define a CSV template, available publicly
and as open-source [58]. The CSV template contains 39
columns which represent the different data fields needed
from the source data for the transformation process. They
inlude the URI of the drug, its brand name, generic
name(s), manufacturer(s), ATC code(s), active ingredi-
ent(s), strength, cost, etc. They are modelled to fit with
the RDF schema, which encompasses all data necessary
for high-quality modeling of the domain.
The data type of the different columns is usually a sim-
ple text value, except where we note otherwise. Some
important notes regarding the field data types include:
the strength value is divided into an integer-value col-
umn denoting the strength, while the unit is part of a
text-value column denoting the strenght unit; similarly,
the cost of the drug is separated into a float value and
a currency value; the several date columns need to be
formatted as “YYYY-MM-DD”; the prescription status
should be enumerated as either “OTC” or “Prescrip-
tionOnly”; the currency code needs to comply with the
ISO standard for denoting currencies [102]; the coun-
try where the drug is registered in needs to be denoted
using a country code accoding to an ISO standard [63]; if
there are multiple generic names, manufacturers or active
ingredients, they should be denoted one-per-column in
the available genericNameN, manufacturerN and
activeIngredientN columns, respectively, etc. The
details about the other column data types are available on
the project website [58].
The CSV template uses a vertical line character (|)
as a delimiter, since the regular CSV separators such
as a comma (,) and a semicolon (;) are very often
present in the cell values when working with drug data,
and can be misinterpreted. It is important to note that
the order of the columns in the CSV template is not
relevant, if used with our OpenRefine transformation
script.
As with the RDF schema, the CSV template is open and
publicly available, and therefore can be extended or modi-
fied in the future by both us and third-parties, as the drug
data field evolves and more Linked Drug Data dataset are
being created.
OpenRefine transformation script
Step III of the methodology contains the task of trans-
forming the source data into the RDF schema selected
in Step II. Since we defined an RDF schema which can
be applied in the drug data domain for drug products
which are registered in different countries, we also provide
a tool which can help automate the transformation pro-
cess, while ensuring compliance of the generated data with
the defined RDF schema and therefore providing aligned,
high-quality 5-star Linked Data for the drug domain. The
intent of this tool is to lower the bounds of transforming
data into RDF and Linked Data for data publishers which
are not deeply involved and experienced in the Semantic
Web and Linked Data practices.
We provide this Linked Data generation tool in the form
of an OpenRefine transformation script. OpenRefine [81]
is an open-source software for working with structured
data, usually CSV, TSV, XML, etc. It provides users with
functionalities for working with large datasets: the users
can record their action over a small set of example rows,
and then apply them over the entire source data. Here, the
actions can include data transformations, merging, data
cleaning tasks, manipulation of the columns, etc. It also
has an RDF extension which allows reconciliation of cell
values against RDF data from SPARQL endpoints. This
allows linking of cell values with entities from a SPARQL
endpoint, for unambiguous identification of entities. It
also allows mapping of the source data into RDF, by defin-
ing an ‘RDF skeleton’. The output of this action is an
RDF file generated from the source data, according to the
definitions in the ‘RDF skeleton’.
The ability of OpenRefine to save the user actions and
then export them in JSON format, allows reuse of certain
sets of actions for different datasets. This gives us the abil-
ity to define the data transformation which can be reused
over different source drug datasets, which have the same
columns. As we have a CSV template, we can use this as
part as our set of tools. The defined list of data transforma-
tion actions we created is what we have as our OpenRefine
transformation script [58].
Our OpenRefine transformation script is designed for
data complying with the CSV template, and its output is
a Linked Drug Data dataset which uses our RDF schema.
The transformation script contains three actions:
A. reconcile the columns genericName1,
genericName2, ..., genericName5 against
DBpedia,
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B. reconcile the column atcCode against the
DrugBank dataset, and
C. create an RDF schema skeleton
Action A. uses the RDF extension feature of OpenRe-
fine which uses the cell value from a selected column
to find potential entities from a given SPARQL endpoint
which can be matched to the entity denoted by the row.
In our case, we use the five genericName columns -
which hold the generic name of the active ingredient of
the drug entity - and we try to match each of them to a
dbo:Drug entity from the DBpedia SPARQL endpoint,
using its rdfs:label value. If the reconciliation service
finds a matching candidate entity, we use it in step C. to
create an RDF triple which links the drug entity from our
CSV dataset with the matched candidates from DBpedia,





mkd:55446 rdfs:seeAlso dbp:Clopidogrel .
Action B. does a similar reconciliation, but on the
atcCode column from the CSV dataset and against the
DrugBank endpoint. It tries to find matches between
the value of the atcCode column on our side and
the drugbank:atcCode value of drugbank:drugs
instances from the endpoint. Unlike the situation in A.,
here we can have more than one matching candidate
from DrugBank. The reason is that there can be multiple
drugbank:drugs instances which have the same ATC
code, i.e. share the same therapeutic, pharmacological and
chemical properties. Similar as in A., we use all matching
candidates from the reconciliation in step C. to create RDF
triples which link the drug entity from our CSV dataset to







mkd:841690570 rdfs:seeAlso dbd:DB00201 ;
rdfs:seeAlso dbd:DB00316 .
Action C. creates the RDF schema skeleton, which con-
tains the rules for mapping the consolidated CSV file into
RDF. In the RDF schema skeleton (Fig. 2), we define map-
pings between the CSV columns and certain RDF triple
patterns. Some of the mappings are straight-forward, such
as the mappings of the brand name, the generic name,
the dosage form, the country, the url, the description, etc.
For them, we define the URI of the drug as a subject,
we denote a specific property for the triple, and then we
define the value of the column as a literal or an object
of the triple. For instance, the brand name of a drug is






However, other mappings are more complex. Mappings
of values such as the ATC code, the cost, the strength,
the manufacturer, the license details, etc., need new enti-
ties to be created, entities of different types. For instance,
in order to add the information about the ATC code to
the drug entity, we need to create a new blank node of
type schema:MedicalCode, which has two additional
triples: one with the schema:codeValue property and
one with the schema:codingSystem property. This
ATC code mapping can be represented with:
Mapping Example 2





The license mappings were the most complex, which
we can see from Fig. 2. Aside from using OpenRefine’s
user interface for defining the RDF skeleton, we used
its GREL language for mapping the reconciliation results
from actions A. and B. into rdfs:seeAlso triples.
As a result of the transformation script, a Linked Data
dataset with links to the LOD Cloud is created. Similarly
as the other tools, the transformation script is available
as an open-source JSON file, which can be extended
and modified in the future. As a support for it, we
also developed a BASH script which sends the CSV file
with drug data, formatted according to our CSV tem-
plate, along with the OpenRefine transformation script
to a running BatchRefine service [58]. The result from
this call is the RDF output representing the transformed
dataset.
SPARQL-based tool for extending and interlinking the dataset
Once the drug dataset is transformed into a Linked Data
dataset with the other tools, an additional step is required
in Step III to create the internal links between drugs
which share the same functionality, i.e. share the same
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therapeutic, pharmacological and chemical properties, in
order to create a better basis for use-cases.We need to cre-
ate links between drugs from the dataset which have the
same function, i.e. are aimed to treat the same condition.
To create these links, we use drug’s ATC codes. Accord-
ing to theWorld Health Organization coding scheme [88],
if two drugs have the same ATC code, they share the
same function. For this purpose, we define a reusable
SPARQL query [58] which detects all pairs of drugs from
the dataset which have the same ATC code, and using
the schema:relatedDrug property creates a pair of









These two triples create a two-way link between the
drugs in the dataset, denoting their functional similarity.
The SPARQL query results with storing the newly created
RDF triples in the same RDF graph where the dataset is
already stored. These interlinkings can be utilizes for pro-
viding the users with alternative drugs they may require
for treating their condition, either in the same of in a
different country.
Since not all source registries contain the ATC code
information, and in order to increase the number of inter-
linked drug products from the dataset and support better
data analytics, we define an additional reusable SPARQL
query [58] which assignes ATC codes to all drugs from
the dataset which miss this information. The SPARQL
query detects drug products without an ATC code, finds
the generic drug from DBpedia which the drug is linked
to with the rdfs:seeAlso relation, gets the ATC code
of the DBpedia generic drug and assigns it to the drug
product in question. Since the SPARQL query for inter-
linking drugs from the dataset depends on the ATC code,
this SPARQL query for extending the dataset with missing
ATC code values should be executed first.
Both SPARQL queries are parametrized and should be
edited before execution. They can be executed over the
Linked Data storage used for storing the Linked Data
dataset generated with the other tools.
Web-based tool for automated transformation, interlinking
and publishing
The generated Linked Drug Data dataset needs to be pub-
lished on theWeb according to the Linked Data principles
and best practices, as advised in Step IV. In order to aid the
data publishers, this step can be automatically executed
by using a web-based tool we provide. The data publish-
ers can upload the generated Linked Data dataset(s) on
the LinkedDrugs project website [60], and after a human-
based quality assessment, the dataset will be automatically
published. For this we use a publicly available Virtuoso
instance [61], from which the new dataset is available on
the Web as Linked Data, via its SPARQL endpoint [62].
The RDF graph identifier is returned to the data publisher
after the successful upload process.
Besides publishing finished Linked Drug Data datasets,
the web-based tool and its automated process can also
execute the previous steps of the methodology for the
data publisher: (a) they can generate an interlinked
Linked Data dataset from an input CSV file, and (b)
they can interlink drugs with schema:relatedDrug
relations from an input RDF file. For the former, the
uploaded CSV file needs to be generated following our
CSV template, and based on it, the predefined RDF
schema and the OpenRefine transformation script, our
web-based tool and its server-side process will gener-
ate the Linked Data dataset. Using the SPARQL-based
tool from above, it will then generate links between
the drugs from the dataset, based on their ATC codes.
For the latter, the web-based tool directly creates the
schema:relatedDrug relations between similar drugs
from the uploaded Linked Drug Data dataset in RDF.
With this, we provide the convenience to move most
of the data processing from the methodological guide-
lines away from the data publishers, and simplify their
workflow.
When a data publisher uses our web-based tool at
[60] to publish a Linked Drug Data dataset, our sys-
tem also adds it to the global Linked Drug Data dataset
- the LinkedDrugs dataset - by storing it in another
RDF graph and generating schema:relatedDrug
triples for linking the drugs from the new dataset with
the drugs from the existing datasets in LinkedDrugs,
and vice-versa. The LinkedDrugs dataset then contains
data for drug products provided by different publish-
ers, including our team, and is available via a perma-
nent, dereferenceable URI, which supports HTTP content
negotiation [65].
Endnote
1Austria, Azerbaijan, Belgium, Canada, Costa Rica,
Croatia, Cyprus, Czech Republic, Egypt, Estonia, EU’s
European Medicines Agency, France, Hungary, Ireland,
Italy, Macedonia, Malta, Netherlands, New Zealand,
Nigeria, Norway, Romania, Russia, Serbia, Slovakia,
Slovenia, South African Republic, Spain, Uganda, Ukraine
and USA.
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